MedRhythms Launches Clinical Trial of Stroke Asset on Walking Outcomes
MedRhythms, a digital therapeutics company building direct stimulation solutions that use clinical-grade sensors, software and music to help restore function lost to neurologic disease or injury, announces the launch of a clinical trial that will study MR-010, MedRhythms’ acute stroke asset.
The trial, conducted in partnership with and funded by UMass Memorial Healthcare, will examine the impact of MR-010 on acute stroke walking outcomes.
Led by Dr. Brian Silver, Interim Chair in the UMass Department of Neurology, the trial will assess the feasibility of MR-010 to address walking impairments in those in the acute phase of stroke. It will consist of two phases: the first phase will look at the impact of MR-010 within the acute hospital setting, and the second phase will look at the continued impact of the therapeutic post-discharge, MedRhythms notes in a media release.